Condition: Non-Small Cell Lung Cancer · Sponsor: AbbVie
Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan as a monotherapy or in combination with osimertinib compared to standard of care (SOC). Telisotuzumab adizutecan is an investigational drug being developed for the treatment of NSCLC. This study will be divided into two stages, in the first stage (phase 2) participants will receive 1 of 2 doses of telisotuzumab adizutecan as a monotherapy or in combination with osimertinib. In the second stage (phase 3) participants will receive the recommended phase 3 dose (RP3D) of telisotuzumab adizutecan, from the previous stage, or SOC. Approximately 490 adult participants with NSCLC will be enrolled in the study in 200 sites around the world. In phase 2, participants will receive 1 of 2 intravenous (IV) doses of telisotuzumab adizutecan as a monotherapy or in combination with oral osimertinib. In phase 3, participants will receive the IV RP3D of telisotuzumab adizutecan, or SOC. The study will run for a duration of approximately 69 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires an…
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| Highlands Oncology Group - Springdale /ID# 277132 | Springdale, Arkansas, United States | Recruiting |
| City of Hope National Medical Center /ID# 277005 | Duarte, California, United States | Recruiting |
| City of Hope - Orange County Lennar Foundation Cancer Center /ID# 277928 | Irvine, California, United States | Recruiting |
| Cancer Specialists of North Florida /ID# 277332 | Jacksonville, Florida, United States | Recruiting |
| Cancer Care Centers of Brevard- Rockledge /ID# 277853 | Rockledge, Florida, United States | Recruiting |
| Moffitt Cancer Center /ID# 276785 | Tampa, Florida, United States | Recruiting |
| Parkview Research Center /ID# 277651 | Fort Wayne, Indiana, United States | Recruiting |
| HealthPartners Cancer Research Center /ID# 277339 | Saint Louis Park, Minnesota, United States | Recruiting |
| Nho - Revive Research Institute /ID# 277569 | Lincoln, Nebraska, United States | Recruiting |
| Dartmouth-Hitchcock Medical Center /ID# 277673 | Lebanon, New Hampshire, United States | Recruiting |
| Astera Cancer Care /ID# 277570 | East Brunswick, New Jersey, United States | Recruiting |
| Tennessee Cancer Specialists - Knoxville - Old Weisgarber Road /ID# 277891 | Knoxville, Tennessee, United States | Recruiting |
+ 98 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07155187